These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 2445283)
41. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. Fabrizi F; Dixit V; Martin P; Messa P J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701 [TBL] [Abstract][Full Text] [Related]
42. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241 [TBL] [Abstract][Full Text] [Related]
44. Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA. Bodeau S; Lemouel JP; Diouf M; Duverlie G; Nguyen-Khac E; Brochot E J Med Virol; 2017 Jun; 89(6):1033-1039. PubMed ID: 27805268 [TBL] [Abstract][Full Text] [Related]
45. Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML Hepatology; 2011 May; 53(5):1774-5; author reply 1775-6. PubMed ID: 21520186 [No Abstract] [Full Text] [Related]
46. Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy. Rafique G; Bukhsh A; Gul A; Khiljee S; Ashraf M; Omer MO Pak J Pharm Sci; 2017 Jan; 30(1):11-16. PubMed ID: 28603106 [TBL] [Abstract][Full Text] [Related]
47. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Gowen BB; Westover JB; Sefing EJ; Van Wettere AJ; Bailey KW; Wandersee L; Komeno T; Furuta Y Antiviral Res; 2017 Sep; 145():131-135. PubMed ID: 28780425 [TBL] [Abstract][Full Text] [Related]
49. A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C. Ide T; Okamura T; Kumashiro R; Koga Y; Hino T; Hisamochi A; Ogata K; Tanaka K; Kuwahara R; Seki R; Sata M Int J Mol Med; 2003 Jun; 11(6):729-32. PubMed ID: 12736713 [TBL] [Abstract][Full Text] [Related]
50. Ribavirin: an antiviral agent with promise. Mack JE Pediatr Nurs; 1988; 14(3):220-1. PubMed ID: 3380572 [No Abstract] [Full Text] [Related]
51. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat. Gruber WC; Wilson SZ; Throop BJ; Wyde PR Pediatr Res; 1987 Mar; 21(3):270-4. PubMed ID: 3550674 [TBL] [Abstract][Full Text] [Related]
52. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. Huggins JW; Hsiang CM; Cosgriff TM; Guang MY; Smith JI; Wu ZO; LeDuc JW; Zheng ZM; Meegan JM; Wang QN J Infect Dis; 1991 Dec; 164(6):1119-27. PubMed ID: 1683355 [TBL] [Abstract][Full Text] [Related]
53. Ribavirin therapy for lassa fever. Snell N Practitioner; 1988 Apr; 232(1447):432. PubMed ID: 3249720 [No Abstract] [Full Text] [Related]